UT Health Science Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shaheen, Montaser
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT06035744: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
86
US
CLN-617, Pembrolizumab, Keytruda
Cullinan Therapeutics Inc.
Advanced Solid Tumor
06/28
06/28
Abdul-Ghani, Muhammad
NCT03193684: Empagliflozin and Hepatic Glucose Metabolism

Completed
4
72
US
Empagliflozin 25 MG, Control, Placebo
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatic Glucose Metabolism
01/23
01/24
NCT03878459: Dapagliflozin Plus Pioglitazone in T1DM

Recruiting
4
120
US, RoW
Pioglitazone 45 mg, Placebo
The University of Texas Health Science Center at San Antonio
Type 1 Diabetes Mellitus
06/27
12/27
NCT06246799: Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Recruiting
3
256
US
Tirzepatide, Mounjaro, Pioglitazone, Actos, Sitagliptin, Januvia, Metformin HCI XR, Extended Release Metformin
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes (Adult Onset)
04/29
06/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shaheen, Montaser
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT06035744: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
86
US
CLN-617, Pembrolizumab, Keytruda
Cullinan Therapeutics Inc.
Advanced Solid Tumor
06/28
06/28
Abdul-Ghani, Muhammad
NCT03193684: Empagliflozin and Hepatic Glucose Metabolism

Completed
4
72
US
Empagliflozin 25 MG, Control, Placebo
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatic Glucose Metabolism
01/23
01/24
NCT03878459: Dapagliflozin Plus Pioglitazone in T1DM

Recruiting
4
120
US, RoW
Pioglitazone 45 mg, Placebo
The University of Texas Health Science Center at San Antonio
Type 1 Diabetes Mellitus
06/27
12/27
NCT06246799: Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Recruiting
3
256
US
Tirzepatide, Mounjaro, Pioglitazone, Actos, Sitagliptin, Januvia, Metformin HCI XR, Extended Release Metformin
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes (Adult Onset)
04/29
06/29

Download Options